VEGFR1

VEGF Trap (aflibercept) not only binds multiple isoforms of VEGF-Abut also inhibits the activation of VEGFR1 and VEGFR2.

(3) Reduction expression of angiogenesis activators: interferons ([alpha], [beta], and [gamma]) decreased expression of angiogenesis activators such as bFGF [80]; a soluble form of VEGFR1 (sVEGFR1) with high affinity for VEGFA has been shown to inhibit angiogenesis through the regulation of VEGFR2 activation and inhibition of downstream mitogenic activities [81]; endostatin blocks action of VEGF [82] whereas interleukin-10 downregulates synthesis of VEGF and matrix metalloproteinase 9 (MMP-9) [83].

the expression of both VEGF-B and VEGFR1 was explored in the murine heart, lung, and kidney.

VEGF binds to 2 major receptor tyrosine kinases, VEGFR1 and VEGFR2 (Ferrara et al., 2003).

VEGF is a major angiogenesis inducer through binding to its receptors (VEGFR1 and VEGFR2) and activation of downstream signaling pathways.

Suppress NFAT-dependent VEGFR1 expression and constitutive VEGFR signaling in infantile hemangioma.

Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2 and VEGFR3.

Sunitinib is a tyrosine kinase inhibitor with broader spectrum tyrosine kinase inhibition and also targets vascular endothelial growth factor receptor (VEGFR1), VEGFR2, FLT3, and RET.

Socha et al., "A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus," Journal of Zhejiang University.

Although VEGF is recognized by three receptors expressed on the surfaces of endothelial cells, VEGFR1 (Flt-1), VEGFR2 (KDR) and VEGFR3 (Flt-4), KDR is considered as the important component in the activation of endothelial cells (Ferrara and Davis-Smyth 1997).